On 18 November 2026 the European Commission granted a marketing authorisation for ensartinib capsules, a Chinese-developed ALK inhibitor filed by Xcovery Holdings, a subsidiary of 贝达药业 (Beta Pharmaceuticals). The authorisation carries the reference number EU/1/26/2078 and covers ALK-positive advanced non-small cell lung cancer (NSCLC) in adults; the drug had already received US FDA approval in December 2024, and the report describes it as the first domestically developed ALK inhibitor approved in China, the United States and the EU (source). Most coverage stopped at that milestone. There is a second reading, and for a patient weighing an ALK lung cancer treatment in China against treatment at home, it is the one that actually changes your questions: China already cleared a broader label for the same molecule. In September 2026 — roughly two months before the EU decision — Chinese regulators approved ensartinib as adjuvant therapy for ALK-positive stage IB to IIIB NSCLC after surgical removal of the tumour. That is an earlier-stage use, and Europe's current authorisation is written for advanced disease.
What the approval record says, and what it does not
The value of a regulatory document to a patient is narrow and specific: it tells you which molecule, in which line of therapy, in which stage of disease, was judged acceptable by which authority. Read that way, the ensartinib timeline is instructive.
- China: three approved indications, dated November 2020, March 2022 and September 2026. The most recent one is the post-surgical adjuvant setting for ALK-positive stage IB–IIIB disease.
- United States: approval in December 2024.
- European Union: EMA marketing-authorisation application opened February 2025, a positive CHMP opinion in September 2026, Commission authorisation reported 18 November 2026 as EU/1/26/2078, for ALK-positive advanced NSCLC in adults.
Two honest caveats. The Chinese indications from 2020 and 2022 are not itemised in the source, so this article does not describe them. And a broader label is not a broader entitlement: it defines what prescribers may lawfully prescribe, not what any particular hospital stocks or what any individual patient should receive.
Comparison of the approval records
| China | European Union | |
|---|---|---|
| First authorisation | November 2020 | Reported 18 November 2026 |
| Number of indications approved | Three (Nov 2020, Mar 2022, Sep 2026) | One reported |
| Newest indication | Adjuvant therapy, ALK-positive stage IB–IIIB NSCLC after tumour resection (Sep 2026) | ALK-positive advanced NSCLC in adults |
| Disease stage covered by newest approval | Resected, earlier-stage disease | Advanced disease |
| Authorisation reference | Ask the dispensing pharmacy for the number printed on the packaging | EU/1/26/2078 |
| Elapsed time in the current review | Not disclosed in the source | About 21 months from the Feb 2025 EMA filing to the Nov 2026 decision |
The last row is a scheduling fact, not a judgment about either regulator's rigour. A European review took roughly two years because it started in February 2025. If a regimen you need is already inside a label where you live, waiting weeks for local access usually beats travelling. The calculation flips when the use you need is not in your national label at all.
Why the origin country is usually ahead on indications
This pattern is not peculiar to ensartinib. A domestic developer runs the pivotal programme, registers the trials and files the first marketing application at home; later filings elsewhere follow, often with indications trimmed to the datasets each agency reviewed separately. China's role in that pipeline has grown structurally. A tally cited by Sina Finance from industry-data provider 医药魔方 puts Chinese innovative-drug out-licensing deals at 150 in the first three quarters of 2026, worth US$135.32 billion in potential value — close to the full-year 2025 figure of US$143.5 billion. China's share of global new-drug transactions reached 33%, against 3% in 2017 (source).
Two numbers in that report deserve a patient's scepticism rather than enthusiasm. Upfront cash was US$8.48 billion, about 6.3% of headline value, and more than 90% of the total is tied to research, registration and sales milestones — money that only arrives if the programmes succeed. What the trend does establish, however, is where first-in-human and early post-marketing experience with new Chinese molecules accumulates: in Chinese hospitals. For a patient, that translates into concrete questions to ask a doctor or an intermediary — is this molecule originally developed in China, and which lines of therapy carry it in the Chinese label?
Those are the right questions because they are checkable. If you are evaluating other modalities on the same logic, our guides to proton therapy in China and CAR-T therapy costs work through availability and pricing in the same way.
Use the authorisation number as your authenticity check
For a medicine taken over months, the practical risk is not the regulator's decision; it is the chain between the pharmacy and your hand. Every marketed pack carries an authorisation or registration identifier assigned by the approving authority. In this news cycle that identifier is visible in the EU filing — EU/1/26/2078 — and the equivalent reference for any product you receive in China is printed on the packaging and recorded by the dispensing hospital.
A workable personal protocol:
- Before the first dose, photograph the carton and the label showing the approval number, product name, strength and batch.
- Ask the dispensing pharmacist to state the number aloud and confirm it matches your written prescription.
- Check the number against the relevant regulator's public register — the EU database for an EU number, the Chinese national drug regulator's register for a Chinese one.
- Keep the record with your imaging and pathology files, so any later prescriber in any country can trace exactly which product you took.
This costs ten minutes and is verifiable. It is also the part of the process where a bilingual coordinator earns their fee; booking through an international medical department rather than a walk-in counter changes what documentation you can obtain.
Who should realistically consider treatment in China
Three profiles tend to hold up under scrutiny.
Resected early-stage ALK-positive disease. If you have had surgery for stage IB–IIIB NSCLC and adjuvant targeted therapy is under discussion, the Chinese label covers that exact setting, so it is a legitimate question for a case review.
You are later in the line and options have narrowed. If standard lines at home are exhausted, the more relevant Chinese conversation is usually clinical trials or cell-based therapy rather than a marketed tablet; our cancer treatment in China service page and the broader medical tourism guide map that terrain.
Price or waiting time is the binding constraint. Honest answer: not addressed by this news. Costs depend on dose, weight, regimen length and facility, and are quoted by the treating hospital.
Against those: continuity of supply across borders, management of resistance if the disease progresses on an ALK inhibitor, interaction checks with your existing medicines, and the surveillance bloodwork and imaging that adjuvant therapy requires. Long-haul travel during active treatment is itself a clinical variable. And a drug's approval status cannot decide your case: a specific treatment plan must be assessed in person by a licensed physician who has reviewed your pathology, staging and full history. A label that says a use is permitted is not a label that says it is right for you. Start with the questions, not with the flights, and settle entry paperwork separately — our medical visa guide covers the documentation side.
Next step
OriEast is not a prescriber and does not promise outcomes. What we do is coordinate: pull your records and translate the pathology, imaging and gene-test reports, arrange the hospital appointment and an oncology consultation in a department that sees international patients, obtain the drug's authorisation documentation so you can verify it yourself, and provide on-the-ground interpretation and logistics for the visit and its follow-ups.
If you want to know whether a given indication — an ALK inhibitor in the adjuvant setting, or anything else in your plan — is actually available to you in China, the only useful first move is to have the file read by clinicians before you budget travel.
- Submit your case for evaluation at /case-evaluation. Include diagnosis, stage, molecular test results, prior treatments and dates.
- Ask anything else at /inquiry — appointment routes, documentation, translation, coordination of care.